The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Antiangiogenic and Antitumor Effects of Bevacizumab in Patients With Inflammatory and Locally Advanced Breast Cancer
Open accessAbstract
Purpose: Vascular endothelial growth factor (VEGF) is a potent molecule that mediates tumor angiogenesis primarily through VEGF receptor 2 (VEGFR2). Bevacizumab, a recombinant humanized monoclonal antibody to VEGF, was administered to previously untreated patients to evaluate parameters of angiogenesis. Patients and Methods: Twenty-one patients with inflammatory and locally advanced breast cancer were treated with bevacizumab for cycle 1 (15 mg/kg on day 1) followed by six cycles of bevacizumab with doxorubicin (50 mg/m 2) and docetaxel (75 mg/m 2) every 3 weeks. After locoregional therapy, patients received eight cycles of bevacizumab alone, and hormonal therapy when indicated. Tumor biopsies and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) were obtained at baseline, and after cycles 1, 4, and 7. Results: A median decrease of 66.7% in phosphorylated VEGFR2 (Y951) in tumor cells (P = .004) and median increase of 128.9% in tumor apoptosis (P = .0008) were seen after bevacizumab alone. These changes persisted with the addition of chemotherapy. There were no significant changes in microvessel density or VEGF-A expression. On DCE-MRI, parameters reflecting reduced angiogenesis, a median decrease of 34.4% in the inflow transfer rate constant (P = .003), 15.0% in the backflow extravascular- extracellular rate constant (P = .0007) and 14.3% in extravascular-extracellular volume fraction (P = .002) were seen after bevacizumab alone. Conclusion: Bevacizumab has inhibitory effects on VEGF receptor activation and vascular permeability, and induces apoptosis in tumor cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
The Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Self-citationMolecular and Biological Properties of the Vascular Endothelial Growth Factor Family of Proteins
FERRARA, N., HOUCK, K., JAKEMAN, L., & LEUNG, D. W. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-1-18 · Cited by 1,655
American Joint Committee On Cancer (2010) · Springer eBooks · doi:10.1007/978-0-387-88443-1 · Cited by 1,386
Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306
Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
Millauer, B., Shawver, L. K., Plate, K. H., Risaui, W., & Ullrich, A. (1994) · Nature · doi:10.1038/367576a0 · Cited by 1,221
Hance, K. W., Anderson, W. F., Devesa, S. S., Young, H. A., & Levine, P. H. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji172 · Cited by 689
Gasparini, G., Bonoldi, E., Gatti, C., Vinante, O., Toi, M., Tominaga, T., Gion, M., Dittadi, R., Verderio, P., Boracchi, P., et al. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.2.139 · Cited by 494
Dias, S., Hattori, K., Heissig, B., Zhu, Z., Wu, Y., Witte, L., Hicklin, D. J., Tateno, M., Bohlen, P., Moore, M. A. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191117498 · Cited by 268
Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma.
Linderholm, B., Tavelin, B., Grankvist, K., & Henriksson, R. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.3121 · Cited by 264
Linderholm, B., Grankvist, K., Wilking, N., Johansson, M., Tavelin, B., & Henriksson, R. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1423 · Cited by 254
Neoadjuvant Trastuzumab Induces Apoptosis in Primary Breast Cancers
Mohsin, S. K., Weiss, H. L., Gutierrez, M. C., Chamness, G. C., Schiff, R., DiGiovanna, M. P., Wang, C.-X., Hilsenbeck, S. G., Osborne, C. K., Allred, D. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.661 · Cited by 244
Price, D. J., Miralem, T., Jiang, S., Steinberg, R., & Avraham, H. K. (2001) · PubMed · Cited by 243
Chang, S., Parker, S. L., Pham, T. H., et al. (1998) · PubMed · Cited by 226
Low, J. A., Wedam, S. B., Lee, J. J., Berman, A. W., Brufsky, A., Yang, S. X., Poruchynsky, M. S., Steinberg, S. M., Mannan, N., Fojo, T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.024 · Cited by 215
Self-citationKleer, C. G., van Golen, K. L., & Merajver, S. D. (2000) · Breast Cancer Research · doi:10.1186/bcr89 · Cited by 212
Chang, S., Parker, S. L., Pham, T., Buzdar, A. U., & Hursting, S. D. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980615)82:12<2366::aid-cncr10>3.0.co;2-n · Cited by 198
Borgström, P., Gold, D. P., Hillan, K. J., & Ferrara, N. (1999) · PubMed · Cited by 196
Tan, A. R., Yang, X., Hewitt, S. M., Berman, A., Lepper, E. R., Sparreboom, A., Parr, A. L., Figg, W. D., Chow, C., Steinberg, S. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.189 · Cited by 176
Self-citation(2002) · PubMed · Cited by 175
Port, R. E., Knopp, M. V., Hoffmann, U., Milker-Zabel, S., & Brix, G. (1999) · Journal of Magnetic Resonance Imaging · Cited by 154
Nakopoulou, L., Stefanaki, K. S., Panayotopoulou, E. G., Giannopoulou, I., Athanassiadou, P. P., Gakiopoulou, H., & Louvrou, A. (2002) · Human Pathology · doi:10.1053/hupa.2002.126879 · Cited by 107
McCarthy, N. J., Yang, X., Linnoila, I. R., et al. (2002) · PubMed · Cited by 81
Self-citationKyzas, P., Stefanou, D., Batistatou, A. K., & Agnantis, N. J. (2004) · Modern Pathology · doi:10.1038/modpathol.3800295 · Cited by 61
Fox, S. B., Turley, H., Cheale, M., Blázquez, C., Roberts, H., James, N. H., Cook, N., Harris, A. L., & Gatter, K. C. (2004) · The Journal of Pathology · doi:10.1002/path.1520 · Cited by 55
Huh, J.-I., Calvo, A., Stafford, J. A., Cheung, M., Kumar, R., Philp, D., Kleinman, H. K., & Green, J. E. (2004) · Oncogene · doi:10.1038/sj.onc.1208221 · Cited by 44
Pharmacokinetics (PK) of the angiogenesis inhibitor ABT-510 in healthy subjects
Karyekar, C. S., Carr, R. A., Andre, A., Wang, Q., Facey, I., Marsh, K. G., Daszkowski, D. J., & Humerickhouse, R. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.3080 · Cited by 10
Cited by
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Marcello, J., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2440 · Cited by 1,394
Goel, H. L., & Mercurio, A. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3627 · Cited by 1,253
Antiangiogenic therapy in oncology: current status and future directions
Jayson, G. C., Kerbel, R., Ellis, L. M., & Harris, A. L. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01088-0 · Cited by 828
Rapid vascular regrowth in tumors after reversal of VEGF inhibition
Mancuso, M. R., Davis, R., Norberg, S. M., O'Brien, S., Sennino, B., Nakahara, T., Yao, V. J., Inai, T., Brooks, P., Freimark, B., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24612 · Cited by 809
Metadata
- Authors
- Wedam, S. B., Low, J. A., Yang, S. X., Chow, C. K., Choyke, P., Danforth, D., Hewitt, S. M., Berman, A., Steinberg, S. M., Liewehr, D. J., Plehn, J., Doshi, A., Thomasson, D., McCarthy, N., Koeppen, H., Sherman, M., Zujewski, J., Camphausen, K., Chen, H., & Swain, S. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-02-10
- Volume
- 24
- Issue
- 5
- Pages
- 769-777
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2117188579
- Cited by
- 518
- References
- 30
- FWCI
- 21.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.